Small Lymphocytic Lymphoma Presenting As a Paraneoplastic Syndrome With Acute Central Nervous System Demyelination.
Small Lymphocytic Lymphoma Presenting As a Paraneoplastic Syndrome With Acute Central Nervous System Demyelination. Clin Lymphoma Myeloma Leuk. 2014 Feb 18; Authors: Devito N, Mui K, Jassam Y, Taylor L, Pilichowska M, Cossor F PMID: 24630921 [PubMed - as supplied by publisher]
Publication date: Available online 13 March 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Gopisree Peringeth, Pallawi Torka, Jerry Wong, Francisco J. Hernandez-Ilizaliturri
PMID: 32179034 [PubMed - as supplied by publisher]
Publication date: Available online 19 February 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Vasu Saini, Aditi Dhir, Ariana W. Rudnick, Joshua Lukas, Karlo J. Lizarraga, Jason Margolesky, Deborah O. Heros, James E. HoffmanAbstractParaneoplastic neurologic syndromes are rare but well described presentation of certain malignancies in both children and adults. Cerebellar dysfunction is a common paraneoplastic presentation and has been previously reported in association with small cell lung cancer, breast cancers, ovarian tumors, renal cell carcinoma, follicular lymphoma, and Hodgkin’s lymphoma. There are ...
Paraneoplastic cholestasis is a rare manifestation of Hodgkin ’s lymphoma (HL), especially in the relapsed/refractory setting. Outcomes are generally poor, perhaps related to the narrow therapeutic window of standard chemotherapy drugs in patients with compromised liver function and limited activity of radiotherapy in controlling systemic disease. Here, we p resent the first report of successful treatment of a patient with idiopathic cholestasis in the setting of relapsed HL post autologous stem cell transplant (ASCT) with bridging therapy (cyclophosphamide, methylprednisolone) and sequential nivolumab.
Paraneoplastic cholestasis (PC) is a rare manifestation of Hodgkin lymphoma (HL). It is comprised of 2 distinct pathologic entities: vanishing bile duct syndrome (VBDS) and idiopathic cholestasis (IC) without ductopenia. There are less than 20 published cases of IC in HL, with none reported in relapsed HL. Treatment of PC is challenging as many chemotherapeutic agents are metabolized by the liver. There is no literature available regarding the treatment of IC in relapsed HL. Here, we present the first report of successful treatment of a patient with IC in the setting of relapsed HL post autologous stem cell support (ASCT) ...
In this study we sought to identify mechanisms of disease development by comparing the immune tumor microenvironment (iTME) of patients with POEMS syndrome to that of patients with MGUS.
POEMS syndrome is a rare paraneoplastic syndrome caused by an underlying plasma cell disorder. The combination of a proteasome inhibitor, an IMiD and corticosteroid is known to be highly effective among patients with myeloma.
ConclusionThis retrospective analysis provides important information on the clinical characteristics of POEMS syndrome in Indian patients, which will help the clinician’s decision-making process.
This study is aimed at bringing together various evidences from the field of immunological and hematological research, at exposing contradictions, and at revealing novel insights on the association between ANCA-associated vasculitis and hematologic malignancies. PMID: 31198793 [PubMed - in process]
ConclusionThe data presented here would be key to the clinician’s decision-making process particularly in the Indian context.